CTNM
NASDAQ HealthcareContineum Therapeutics, Inc. - Common stock
Biotechnology
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
�� 市场数据
| 价格 | $13.53 |
|---|---|
| 成交量 | 423,196 |
| 市值 | 505.16M |
| 贝塔系数 | 1.390 |
| RSI（14日） | 52.6 |
| 200日均线 | $11.09 |
| 50日均线 | $13.94 |
| 52周最高 | $16.33 |
| 52周最低 | $3.35 |
| Forward P/E | -6.22 |
| Price / Book | 1.93 |
🎯 投资策略评分
CTNM 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (87/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (13/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CTNM in your text
粘贴任何文章、记录或帖子 — 工具将提取 CTNM 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.